| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| 2413.T - M3, Inc. | HOLD | 0 @ JPY 14.8889 | JPY 0 | The current share valuation price of 2413.T based on adjusted close was JPY 14.8889. The average price that 2413.T shares were previous bought at was JPY 14.6321. The current market price is 1.8% higher than average price they were purchased at. The value of the holding in 2413.T has fallen by JPY 14,036 (USD $90) compared to the previous valuation of M3, Inc. |
| 4151.T - Kyowa Kirin Co., Ltd. | HOLD | 0 @ JPY 16.6122 | JPY 0 | The current share valuation price of 4151.T based on adjusted close was JPY 16.6122. The average price that 4151.T shares were previous bought at was JPY 15.6756. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in 4151.T has increased by JPY 4,487 (USD $29) compared to the previous valuation of Kyowa Kirin Co., Ltd. however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| 4502.T - Takeda Pharmaceutical Company Limited | HOLD | 0 @ JPY 28.9243 | JPY 0 | The current share valuation price of 4502.T based on adjusted close was JPY 28.9243. The average price that 4502.T shares were previous bought at was JPY 28.7628. The current market price is 0.6% higher than average price they were purchased at. The value of the holding in 4502.T has increased by JPY 7,992 (USD $52) compared to the previous valuation of Takeda Pharmaceutical Company Limited however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| 4503.T - Astellas Pharma Inc. | HOLD | 0 @ JPY 12.9328 | JPY 0 | The current share valuation price of 4503.T based on adjusted close was JPY 12.9328. The average price that 4503.T shares were previous bought at was JPY 10.952. The current market price is 18.1% higher than average price they were purchased at. The value of the holding in 4503.T has increased by JPY 80,660 (USD $520) compared to the previous valuation of Astellas Pharma Inc. however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| 4507.T - Shionogi & Co., Ltd. | HOLD | 0 @ JPY 17.4238 | JPY 0 | The current share valuation price of 4507.T based on adjusted close was JPY 17.4238. The average price that 4507.T shares were previous bought at was JPY 16.9132. The current market price is 3.0% higher than average price they were purchased at. The value of the holding in 4507.T has increased by JPY 7,563 (USD $49) compared to the previous valuation of Shionogi & Co., Ltd. however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| 4519.T - Chugai Pharmaceutical Co., Ltd. | HOLD | 0 @ JPY 54.7835 | JPY 0 | The current share valuation price of 4519.T based on adjusted close was JPY 54.7835. The average price that 4519.T shares were previous bought at was JPY 46.8654. The current market price is 16.9% higher than average price they were purchased at. The value of the holding in 4519.T has increased by JPY 153,323 (USD $988) compared to the previous valuation of Chugai Pharmaceutical Co., Ltd. however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 30.4504 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 30.4504. The average price that 4523.T shares were previous bought at was JPY 30.5058. The current market price is -0.2% lower than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 29,624 (USD $191) compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| 4543.T - Terumo Corporation | HOLD | 0 @ JPY 15.6681 | JPY 0 | The current share valuation price of 4543.T based on adjusted close was JPY 15.6681. The average price that 4543.T shares were previous bought at was JPY 16.5412. The current market price is -5.3% lower than average price they were purchased at. The value of the holding in 4543.T has increased by JPY 10,450 (USD $67) compared to the previous valuation of Terumo Corporation however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| 4568.T - Daiichi Sankyo Company, Limited | HOLD | 0 @ JPY 23.0981 | JPY 0 | The current share valuation price of 4568.T based on adjusted close was JPY 23.0981. The average price that 4568.T shares were previous bought at was JPY 27.437. The current market price is -15.8% lower than average price they were purchased at. The value of the holding in 4568.T has increased by JPY 37,790 (USD $244) compared to the previous valuation of Daiichi Sankyo Company, Limited however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| 4578.T - Otsuka Holdings Co., Ltd. | HOLD | 0 @ JPY 60.3511 | JPY 0 | The current share valuation price of 4578.T based on adjusted close was JPY 60.3511. The average price that 4578.T shares were previous bought at was JPY 55.531. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in 4578.T has increased by JPY 19,446 (USD $125) compared to the previous valuation of Otsuka Holdings Co., Ltd. however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.6091 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.6091. The average price that 6869.T shares were previous bought at was JPY 12.0716. The current market price is -20.4% lower than average price they were purchased at. The value of the holding in 6869.T has increased by JPY 49,478 (USD $319) compared to the previous valuation of Sysmex Corporation however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| 7733.T - Olympus Corporation | HOLD | 0 @ JPY 13.2303 | JPY 0 | The current share valuation price of 7733.T based on adjusted close was JPY 13.2303. The average price that 7733.T shares were previous bought at was JPY 12.7075. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in 7733.T has increased by JPY 8,086 (USD $52) compared to the previous valuation of Olympus Corporation however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| 7741.T - HOYA Corporation | HOLD | 0 @ JPY 154.16 | JPY 0 | The current share valuation price of 7741.T based on adjusted close was JPY 154.16. The average price that 7741.T shares were previous bought at was JPY 142.488. The current market price is 8.2% higher than average price they were purchased at. The value of the holding in 7741.T has increased by JPY 33,117 (USD $214) compared to the previous valuation of HOYA Corporation however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 148.32 | USD 0 | The current share valuation price of A based on adjusted close was USD 148.32. The average price that A shares were previous bought at was USD 136.481. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in A has fallen by USD 52,078 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 228.71 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 228.71. The average price that ABBV shares were previous bought at was USD 207.961. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in ABBV has fallen by USD 223,148 compared to the previous valuation of AbbVie Inc |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 125.4 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 125.4. The average price that ABT shares were previous bought at was USD 131.674. The current market price is -4.8% lower than average price they were purchased at. The value of the holding in ABT has increased by USD 9,668 compared to the previous valuation of Abbott Laboratories however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| ALC.SW - | HOLD | 0 @ CHF 79.2059 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 79.2059. The average price that ALC.SW shares were previous bought at was CHF 77.8949. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in ALC.SW has fallen by CHF 74,144 (USD $92,708) compared to the previous valuation of |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 465.34 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 465.34. The average price that ALNY shares were previous bought at was USD 421.252. The current market price is 10.5% higher than average price they were purchased at. The value of the holding in ALNY has fallen by USD 83,673 compared to the previous valuation of Alnylam Pharmaceuticals Inc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 340.16 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 340.16. The average price that AMGN shares were previous bought at was USD 303.018. The current market price is 12.3% higher than average price they were purchased at. The value of the holding in AMGN has fallen by USD 191,412 compared to the previous valuation of Amgen Inc |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 924.775 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 924.775. The average price that ARGX.BR shares were previous bought at was EUR 849.225. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in ARGX.BR has fallen by EUR 31,860 (USD $37,171) compared to the previous valuation of Argenx SE |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 180.729 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 180.729. The average price that AZN.L shares were previous bought at was GBP 134.428. The current market price is 34.4% higher than average price they were purchased at. The value of the holding in AZN.L has fallen by GBP 263,992 (USD $352,398) compared to the previous valuation of AstraZeneca PLC |
| BAX - Baxter International Inc | HOLD | 0 @ USD 18.48 | USD 0 | The current share valuation price of BAX based on adjusted close was USD 18.48. The average price that BAX shares were previous bought at was USD 19.3923. The current market price is -4.7% lower than average price they were purchased at. The value of the holding in BAX has fallen by USD 6,284 compared to the previous valuation of Baxter International Inc |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 39.1938 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 39.1938. The average price that BAYN.DE shares were previous bought at was EUR 31.6215. The current market price is 23.9% higher than average price they were purchased at. The value of the holding in BAYN.DE has fallen by EUR 14,802 (USD $17,269) compared to the previous valuation of Bayer AG |
| BDX - Becton Dickinson and Company | HOLD | 0 @ USD 193.76 | USD 0 | The current share valuation price of BDX based on adjusted close was USD 193.76. The average price that BDX shares were previous bought at was USD 184.068. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in BDX has increased by USD 1,177 compared to the previous valuation of Becton Dickinson and Company however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 181.98 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 181.98. The average price that BIIB shares were previous bought at was USD 174.271. The current market price is 4.4% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 11,101 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 121.638 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 121.638. The average price that BIM.PA shares were previous bought at was EUR 126.888. The current market price is -4.1% lower than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 5,294 (USD $6,176) compared to the previous valuation of BioMerieux |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 51.95 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 51.95. The average price that BMY shares were previous bought at was USD 47.3933. The current market price is 9.6% higher than average price they were purchased at. The value of the holding in BMY has increased by USD 123,349 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 97.72 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 97.72. The average price that BSX shares were previous bought at was USD 101.08. The current market price is -3.3% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 28,429 compared to the previous valuation of Boston Scientific Corporation |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 97.72 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 97.72. The average price that BSX shares were previous bought at was USD 101.08. The current market price is -3.3% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 28,429 compared to the previous valuation of MULSTRXSSXIMETFP |
| CAH - Cardinal Health Inc | HOLD | 0 @ USD 199.19 | USD 0 | The current share valuation price of CAH based on adjusted close was USD 199.19. The average price that CAH shares were previous bought at was USD 169.573. The current market price is 17.5% higher than average price they were purchased at. The value of the holding in CAH has fallen by USD 25,523 compared to the previous valuation of Cardinal Health Inc |
| CI - Cigna Corp | HOLD | 0 @ USD 268.42 | USD 0 | The current share valuation price of CI based on adjusted close was USD 268.42. The average price that CI shares were previous bought at was USD 290.418. The current market price is -7.6% lower than average price they were purchased at. The value of the holding in CI has fallen by USD 69,160 compared to the previous valuation of Cigna Corp |
| CNC - Concurrent Technologies Plc | HOLD | 0 @ USD 38.85 | USD 0 | The current share valuation price of CNC based on adjusted close was USD 38.85. The average price that CNC shares were previous bought at was USD 39.0959. The current market price is -0.6% lower than average price they were purchased at. The value of the holding in CNC has increased by USD 3,717 compared to the previous valuation of Concurrent Technologies Plc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| COH.AX - | HOLD | 0 @ AUD 180.249 | AUD 0 | The current share valuation price of COH.AX based on adjusted close was AUD 180.249. The average price that COH.AX shares were previous bought at was AUD 184.68. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in COH.AX has fallen by AUD 18,112 (USD $11,963) compared to the previous valuation of |
| COLO-B.CO - | HOLD | 0 @ DKK 91.4575 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 91.4575. The average price that COLO-B.CO shares were previous bought at was DKK 91.9921. The current market price is -0.6% lower than average price they were purchased at. The value of the holding in COLO-B.CO has increased by DKK 57,376 (USD $8,964) compared to the previous valuation of however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| COO - The Cooper Companies, Inc. Common Stock | HOLD | 0 @ USD 77.03 | USD 0 | The current share valuation price of COO based on adjusted close was USD 77.03. The average price that COO shares were previous bought at was USD 75.7419. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in COO has increased by USD 19,664 compared to the previous valuation of The Cooper Companies, Inc. Common Stock however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| COR - Cencora Inc. | HOLD | 0 @ USD 337.63 | USD 0 | The current share valuation price of COR based on adjusted close was USD 337.63. The average price that COR shares were previous bought at was USD 322.771. The current market price is 4.6% higher than average price they were purchased at. The value of the holding in COR has increased by USD 85,188 compared to the previous valuation of Cencora Inc. however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| CSL.AX - | HOLD | 0 @ AUD 122.874 | AUD 0 | The current share valuation price of CSL.AX based on adjusted close was AUD 122.874. The average price that CSL.AX shares were previous bought at was AUD 119.833. The current market price is 2.5% higher than average price they were purchased at. The value of the holding in CSL.AX has increased by AUD 67,096 (USD $44,317) compared to the previous valuation of however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| CVS - CVS Health Corp | HOLD | 0 @ USD 76.75 | USD 0 | The current share valuation price of CVS based on adjusted close was USD 76.75. The average price that CVS shares were previous bought at was USD 71.2654. The current market price is 7.7% higher than average price they were purchased at. The value of the holding in CVS has increased by USD 131,395 compared to the previous valuation of CVS Health Corp however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| DEMANT.CO - | HOLD | 0 @ DKK 33.3198 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 33.3198. The average price that DEMANT.CO shares were previous bought at was DKK 35.3933. The current market price is -5.9% lower than average price they were purchased at. The value of the holding in DEMANT.CO has increased by DKK 9,143 (USD $1,428) compared to the previous valuation of however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| DGX - Quest Diagnostics Incorporated | HOLD | 0 @ USD 184.18 | USD 0 | The current share valuation price of DGX based on adjusted close was USD 184.18. The average price that DGX shares were previous bought at was USD 182.08. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in DGX has increased by USD 3,559 compared to the previous valuation of Quest Diagnostics Incorporated however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 227.13 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 227.13. The average price that DHR shares were previous bought at was USD 210.347. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 61,861 compared to the previous valuation of Danaher Corporation |
| DHR - Danaher Corporation | HOLD | 0 @ USD 227.13 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 227.13. The average price that DHR shares were previous bought at was USD 210.347. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 61,861 compared to the previous valuation of Danaher Corporation |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 249.813 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 249.813. The average price that DIM.PA shares were previous bought at was EUR 221.291. The current market price is 12.9% higher than average price they were purchased at. The value of the holding in DIM.PA has fallen by EUR 1,589 (USD $1,854) compared to the previous valuation of Sartorius Stedim Biotech |
| DXCM - DexCom Inc | HOLD | 0 @ USD 65.25 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 65.25. The average price that DXCM shares were previous bought at was USD 69.0446. The current market price is -5.5% lower than average price they were purchased at. The value of the holding in DXCM has increased by USD 4,646 compared to the previous valuation of DexCom Inc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 353.941 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 353.941. The average price that EL.PA shares were previous bought at was EUR 343.222. The current market price is 3.1% higher than average price they were purchased at. The value of the holding in EL.PA has fallen by EUR 140,975 (USD $164,473) compared to the previous valuation of EssilorLuxottica SA |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 333.49 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 333.49. The average price that ELV shares were previous bought at was USD 379.389. The current market price is -12.1% lower than average price they were purchased at. The value of the holding in ELV has increased by USD 95,365 compared to the previous valuation of Elevance Health Inc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 333.49 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 333.49. The average price that ELV shares were previous bought at was USD 379.389. The current market price is -12.1% lower than average price they were purchased at. The value of the holding in ELV has increased by USD 95,365 compared to the previous valuation of Elevance Health Inc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 68.9204 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 68.9204. The average price that ERF.PA shares were previous bought at was EUR 54.9711. The current market price is 25.4% higher than average price they were purchased at. The value of the holding in ERF.PA has increased by EUR 2,556 (USD $2,982) compared to the previous valuation of Eurofins Scientific SE however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 85.78 | USD 0 | The current share valuation price of EW based on adjusted close was USD 85.78. The average price that EW shares were previous bought at was USD 78.9814. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in EW has increased by USD 171,787 compared to the previous valuation of Edwards Lifesciences Corp however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 46.8108 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 46.8108. The average price that FME.DE shares were previous bought at was EUR 50.6369. The current market price is -7.6% lower than average price they were purchased at. The value of the holding in FME.DE has fallen by EUR 1,276 (USD $1,489) compared to the previous valuation of Fresenius Medical Care AG |
| FPH.NZ - | HOLD | 0 @ NZD 22.0624 | NZD 0 | The current share valuation price of FPH.NZ based on adjusted close was NZD 22.0624. The average price that FPH.NZ shares were previous bought at was NZD 21.0994. The current market price is 4.6% higher than average price they were purchased at. The value of the holding in FPH.NZ has fallen by NZD 656 (USD $379) compared to the previous valuation of |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 55.8694 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 55.8694. The average price that FRE.DE shares were previous bought at was EUR 52.7009. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in FRE.DE has increased by EUR 5,653 (USD $6,595) compared to the previous valuation of Fresenius SE & Co KGaA however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| GALD.SW - | HOLD | 0 @ CHF 204.382 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 204.382. The average price that GALD.SW shares were previous bought at was CHF 184.735. The current market price is 10.6% higher than average price they were purchased at. The value of the holding in GALD.SW has increased by CHF 4,930 (USD $6,164) compared to the previous valuation of however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| GEHC - GE HealthCare Technologies Inc. | HOLD | 0 @ USD 82.52 | USD 0 | The current share valuation price of GEHC based on adjusted close was USD 82.52. The average price that GEHC shares were previous bought at was USD 78.1556. The current market price is 5.6% higher than average price they were purchased at. The value of the holding in GEHC has fallen by USD 10,345 compared to the previous valuation of GE HealthCare Technologies Inc. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 122.62 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 122.62. The average price that GILD shares were previous bought at was USD 116.84. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in GILD has fallen by USD 347,644 compared to the previous valuation of Guild Esports Plc |
| GMAB.CO - | HOLD | 0 @ DKK 322.258 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 322.258. The average price that GMAB.CO shares were previous bought at was DKK 286.349. The current market price is 12.5% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 82,089 (USD $12,825) compared to the previous valuation of however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 12.5257 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 12.5257. The average price that GRF.MC shares were previous bought at was EUR 13.0922. The current market price is -4.3% lower than average price they were purchased at. The value of the holding in GRF.MC has increased by EUR 9,413 (USD $10,982) compared to the previous valuation of Grifols SA however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 24.42 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 24.42. The average price that GSK.L shares were previous bought at was GBP 23.2984. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in GSK.L has fallen by GBP 3,503 (USD $4,676) compared to the previous valuation of GlaxoSmithKline PLC |
| HCA - HCA Holdings Inc | HOLD | 0 @ USD 487.66 | USD 0 | The current share valuation price of HCA based on adjusted close was USD 487.66. The average price that HCA shares were previous bought at was USD 446.536. The current market price is 9.2% higher than average price they were purchased at. The value of the holding in HCA has increased by USD 3,613 compared to the previous valuation of HCA Holdings Inc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| HIK.L - | HOLD | 0 @ GBP 21.2639 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 21.2639. The average price that HIK.L shares were previous bought at was GBP 22.8357. The current market price is -6.9% lower than average price they were purchased at. The value of the holding in HIK.L has increased by GBP 2,777 (USD $3,707) compared to the previous valuation of however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 4.80777 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 4.80777. The average price that HLN.L shares were previous bought at was GBP 4.89079. The current market price is -1.7% lower than average price they were purchased at. The value of the holding in HLN.L has fallen by GBP 1,906 (USD $2,544) compared to the previous valuation of Haleon PLC |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.86 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.86. The average price that HOLX shares were previous bought at was USD 70.4987. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in HOLX has fallen by USD 11,665 compared to the previous valuation of Hologic Inc |
| HUM - Hummingbird Resources PLC | HOLD | 0 @ USD 253.02 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 253.02. The average price that HUM shares were previous bought at was USD 301.5. The current market price is -16.1% lower than average price they were purchased at. The value of the holding in HUM has fallen by USD 68,067 compared to the previous valuation of Hummingbird Resources PLC |
| HUM - Humana Inc | HOLD | 0 @ USD 253.02 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 253.02. The average price that HUM shares were previous bought at was USD 301.5. The current market price is -16.1% lower than average price they were purchased at. The value of the holding in HUM has fallen by USD 68,067 compared to the previous valuation of Humana Inc |
| IDXX - IDEXX Laboratories Inc | HOLD | 0 @ USD 717.47 | USD 0 | The current share valuation price of IDXX based on adjusted close was USD 717.47. The average price that IDXX shares were previous bought at was USD 617.871. The current market price is 16.1% higher than average price they were purchased at. The value of the holding in IDXX has fallen by USD 128,008 compared to the previous valuation of IDEXX Laboratories Inc |
| ILMN - Illumina Inc | HOLD | 0 @ USD 128.03 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 128.03. The average price that ILMN shares were previous bought at was USD 105.053. The current market price is 21.9% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 256 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| INCY - Incyte Corporation | HOLD | 0 @ USD 100.46 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 100.46. The average price that INCY shares were previous bought at was USD 105.014. The current market price is -4.3% lower than average price they were purchased at. The value of the holding in INCY has fallen by USD 12,807 compared to the previous valuation of Incyte Corporation |
| INSM - Insmed Inc | HOLD | 0 @ USD 205.04 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 205.04. The average price that INSM shares were previous bought at was USD 207.77. The current market price is -1.3% lower than average price they were purchased at. The value of the holding in INSM has fallen by USD 19,688 compared to the previous valuation of Insmed Inc |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 142.884 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 142.884. The average price that IPN.PA shares were previous bought at was EUR 136.194. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 1,784 (USD $2,081) compared to the previous valuation of Ipsen SA however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 224.92 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 224.92. The average price that IQV shares were previous bought at was USD 201.584. The current market price is 11.6% higher than average price they were purchased at. The value of the holding in IQV has fallen by USD 96,020 compared to the previous valuation of IQVIA Holdings Inc |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 568.63 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 568.63. The average price that ISRG shares were previous bought at was USD 538.898. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in ISRG has fallen by USD 26,457 compared to the previous valuation of Intuitive Surgical Inc |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 202.48 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 202.48. The average price that JNJ shares were previous bought at was USD 169.964. The current market price is 19.1% higher than average price they were purchased at. The value of the holding in JNJ has fallen by USD 432,285 compared to the previous valuation of Johnson & Johnson |
| LH - Laboratory Corporation of America Holdings | HOLD | 0 @ USD 261.48 | USD 0 | The current share valuation price of LH based on adjusted close was USD 261.48. The average price that LH shares were previous bought at was USD 263.984. The current market price is -0.9% lower than average price they were purchased at. The value of the holding in LH has fallen by USD 7,417 compared to the previous valuation of Laboratory Corporation of America Holdings |
| LLY - Eli Lilly and Company | HOLD | 0 @ USD 1014.49 | USD 0 | The current share valuation price of LLY based on adjusted close was USD 1014.49. The average price that LLY shares were previous bought at was USD 851.851. The current market price is 19.1% higher than average price they were purchased at. The value of the holding in LLY has fallen by USD 1,257,934 compared to the previous valuation of Eli Lilly and Company |
| LONN.SW - | HOLD | 0 @ CHF 684.687 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 684.687. The average price that LONN.SW shares were previous bought at was CHF 675.177. The current market price is 1.4% higher than average price they were purchased at. The value of the holding in LONN.SW has fallen by CHF 10,154 (USD $12,696) compared to the previous valuation of |
| MCK - McKesson Corporation | HOLD | 0 @ USD 814.18 | USD 0 | The current share valuation price of MCK based on adjusted close was USD 814.18. The average price that MCK shares were previous bought at was USD 782.624. The current market price is 4.0% higher than average price they were purchased at. The value of the holding in MCK has increased by USD 137,312 compared to the previous valuation of McKesson Corporation however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 101.99 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 101.99. The average price that MDT shares were previous bought at was USD 97.7117. The current market price is 4.4% higher than average price they were purchased at. The value of the holding in MDT has increased by USD 679 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 100.89 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 100.89. The average price that MRK shares were previous bought at was USD 91.0433. The current market price is 10.8% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 241,433 compared to the previous valuation of Marks Electrical Group PLC |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 100.89 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 100.89. The average price that MRK shares were previous bought at was USD 91.0433. The current market price is 10.8% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 241,433 compared to the previous valuation of Merck & Company Inc |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 139.382 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 139.382. The average price that MRK.DE shares were previous bought at was EUR 130.796. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in MRK.DE has fallen by EUR 1,163 (USD $1,357) compared to the previous valuation of Merck KGaA |
| MTD - Mettler-Toledo International Inc | HOLD | 0 @ USD 1422.81 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1422.81. The average price that MTD shares were previous bought at was USD 1464.54. The current market price is -2.8% lower than average price they were purchased at. The value of the holding in MTD has fallen by USD 28,087 compared to the previous valuation of Mettler-Toledo International Inc |
| MTD - AMUNDI EUR GOV 710 | HOLD | 0 @ USD 1422.81 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1422.81. The average price that MTD shares were previous bought at was USD 1464.54. The current market price is -2.8% lower than average price they were purchased at. The value of the holding in MTD has fallen by USD 28,087 compared to the previous valuation of AMUNDI EUR GOV 710 |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 154.22 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 154.22. The average price that NBIX shares were previous bought at was USD 141.389. The current market price is 9.1% higher than average price they were purchased at. The value of the holding in NBIX has increased by USD 4,278 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| NOVN.SW - | HOLD | 0 @ CHF 133.442 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 133.442. The average price that NOVN.SW shares were previous bought at was CHF 122.898. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in NOVN.SW has fallen by CHF 172,840 (USD $216,115) compared to the previous valuation of |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 47.7917 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 47.7917. The average price that NOVO-B.CO shares were previous bought at was DKK 55.3991. The current market price is -13.7% lower than average price they were purchased at. The value of the holding in NOVO-B.CO has increased by DKK 106,584 (USD $16,652) compared to the previous valuation of Novo Nordisk A/S however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 242.06 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 242.06. The average price that NTRA shares were previous bought at was USD 176.34. The current market price is 37.3% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 12,077 compared to the previous valuation of Natera Inc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 69.6907 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 69.6907. The average price that ORNBV.HE shares were previous bought at was EUR 67.5102. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in ORNBV.HE has fallen by EUR 2,908 (USD $3,393) compared to the previous valuation of Orion Oyj |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.7 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.7. The average price that PFE shares were previous bought at was USD 24.7817. The current market price is 3.7% higher than average price they were purchased at. The value of the holding in PFE has increased by USD 33,142 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 26.5222 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 26.5222. The average price that PHIA.AS shares were previous bought at was EUR 26.6894. The current market price is -0.6% lower than average price they were purchased at. The value of the holding in PHIA.AS has fallen by EUR 26,074 (USD $30,420) compared to the previous valuation of Koninklijke Philips NV |
| PME.AX - | HOLD | 0 @ AUD 166.711 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 166.711. The average price that PME.AX shares were previous bought at was AUD 178.839. The current market price is -6.8% lower than average price they were purchased at. The value of the holding in PME.AX has fallen by AUD 1,635 (USD $1,080) compared to the previous valuation of |
| PODD - Insulet Corporation | HOLD | 0 @ USD 315.92 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 315.92. The average price that PODD shares were previous bought at was USD 333.823. The current market price is -5.4% lower than average price they were purchased at. The value of the holding in PODD has increased by USD 25,088 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 47.1785 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 47.1785. The average price that QIA.DE shares were previous bought at was EUR 45.7321. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in QIA.DE has increased by EUR 55,052 (USD $64,228) compared to the previous valuation of QIAGEN NV however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 57.0601 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 57.0601. The average price that REC.MI shares were previous bought at was EUR 58.3969. The current market price is -2.3% lower than average price they were purchased at. The value of the holding in REC.MI has fallen by EUR 2,981 (USD $3,478) compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 722.8 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 722.8. The average price that REGN shares were previous bought at was USD 714.362. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in REGN has fallen by USD 5,924 compared to the previous valuation of Regeneron Pharmaceuticals Inc |
| RMD - ResMed Inc | HOLD | 0 @ USD 251.51 | USD 0 | The current share valuation price of RMD based on adjusted close was USD 251.51. The average price that RMD shares were previous bought at was USD 256.028. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in RMD has increased by USD 289 compared to the previous valuation of ResMed Inc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 403.021 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 403.021. The average price that RO.SW shares were previous bought at was CHF 343.703. The current market price is 17.3% higher than average price they were purchased at. The value of the holding in RO.SW has fallen by CHF 16,807 (USD $21,015) compared to the previous valuation of |
| ROG.SW - | HOLD | 0 @ CHF 387.165 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 387.165. The average price that ROG.SW shares were previous bought at was CHF 360.262. The current market price is 7.5% higher than average price they were purchased at. The value of the holding in ROG.SW has fallen by CHF 216,629 (USD $270,868) compared to the previous valuation of |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 39.15 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 39.15. The average price that RPRX shares were previous bought at was USD 37.0444. The current market price is 5.7% higher than average price they were purchased at. The value of the holding in RPRX has fallen by USD 3,767 compared to the previous valuation of Royalty Pharma Plc |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 98.7228 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 98.7228. The average price that SAN.PA shares were previous bought at was EUR 99.0728. The current market price is -0.4% lower than average price they were purchased at. The value of the holding in SAN.PA has fallen by EUR 62,737 (USD $73,194) compared to the previous valuation of Sanofi SA |
| SDZ.SW - | HOLD | 0 @ CHF 71.1904 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 71.1904. The average price that SDZ.SW shares were previous bought at was CHF 58.4938. The current market price is 21.7% higher than average price they were purchased at. The value of the holding in SDZ.SW has fallen by CHF 3,498 (USD $4,374) compared to the previous valuation of |
| SHL.AX - | HOLD | 0 @ AUD 15.2591 | AUD 0 | The current share valuation price of SHL.AX based on adjusted close was AUD 15.2591. The average price that SHL.AX shares were previous bought at was AUD 15.0324. The current market price is 1.5% higher than average price they were purchased at. The value of the holding in SHL.AX has increased by AUD 118 (USD $78) compared to the previous valuation of however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 49.7875 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 49.7875. The average price that SHL.DE shares were previous bought at was EUR 53.3465. The current market price is -6.7% lower than average price they were purchased at. The value of the holding in SHL.DE has increased by EUR 3,036 (USD $3,542) compared to the previous valuation of Siemens Healthineers AG however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| SIG.AX - | HOLD | 0 @ AUD 1.82712 | AUD 0 | The current share valuation price of SIG.AX based on adjusted close was AUD 1.82712. The average price that SIG.AX shares were previous bought at was AUD 1.89692. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in SIG.AX has fallen by AUD 13,344 (USD $8,814) compared to the previous valuation of |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 16.4694 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 16.4694. The average price that SN.L shares were previous bought at was GBP 17.3873. The current market price is -5.3% lower than average price they were purchased at. The value of the holding in SN.L has increased by GBP 437 (USD $583) compared to the previous valuation of Smith & Nephew PLC however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| SOBI.ST - | HOLD | 0 @ SEK 36.5041 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 36.5041. The average price that SOBI.ST shares were previous bought at was SEK 33.0478. The current market price is 10.5% higher than average price they were purchased at. The value of the holding in SOBI.ST has increased by SEK 17,502 (USD $1,867) compared to the previous valuation of however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| SOLV - Solventum Corp. | HOLD | 0 @ USD 85.2601 | USD 0 | The current share valuation price of SOLV based on adjusted close was USD 85.2601. The average price that SOLV shares were previous bought at was USD 72.8763. The current market price is 17.0% higher than average price they were purchased at. The value of the holding in SOLV has increased by USD 39 compared to the previous valuation of Solventum Corp. however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| SOON.SW - | HOLD | 0 @ CHF 249.953 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 249.953. The average price that SOON.SW shares were previous bought at was CHF 273.01. The current market price is -8.4% lower than average price they were purchased at. The value of the holding in SOON.SW has increased by CHF 47,004 (USD $58,773) compared to the previous valuation of however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 300.359 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 300.359. The average price that SRT3.DE shares were previous bought at was EUR 257.023. The current market price is 16.9% higher than average price they were purchased at. The value of the holding in SRT3.DE has fallen by EUR 8,843 (USD $10,317) compared to the previous valuation of Sartorius AG |
| STE - STERIS plc | HOLD | 0 @ USD 261.02 | USD 0 | The current share valuation price of STE based on adjusted close was USD 261.02. The average price that STE shares were previous bought at was USD 228.065. The current market price is 14.4% higher than average price they were purchased at. The value of the holding in STE has increased by USD 53,530 compared to the previous valuation of STERIS plc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| STMN.SW - | HOLD | 0 @ CHF 114.689 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 114.689. The average price that STMN.SW shares were previous bought at was CHF 121.502. The current market price is -5.6% lower than average price they were purchased at. The value of the holding in STMN.SW has increased by CHF 7,725 (USD $9,659) compared to the previous valuation of however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| SYK - Stryker Corporation | HOLD | 0 @ USD 364.35 | USD 0 | The current share valuation price of SYK based on adjusted close was USD 364.35. The average price that SYK shares were previous bought at was USD 370.188. The current market price is -1.6% lower than average price they were purchased at. The value of the holding in SYK has fallen by USD 25,371 compared to the previous valuation of Stryker Corporation |
| TEVA - Teva Pharma Industries Ltd ADR | HOLD | 0 @ USD 28.41 | USD 0 | The current share valuation price of TEVA based on adjusted close was USD 28.41. The average price that TEVA shares were previous bought at was USD 19.447. The current market price is 46.1% higher than average price they were purchased at. The value of the holding in TEVA has increased by USD 14,747 compared to the previous valuation of Teva Pharma Industries Ltd ADR however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| TMO - Time Out Group plc | HOLD | 0 @ USD 575.24 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 575.24. The average price that TMO shares were previous bought at was USD 480.381. The current market price is 19.7% higher than average price they were purchased at. The value of the holding in TMO has fallen by USD 113,573 compared to the previous valuation of Time Out Group plc |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 280.047 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 280.047. The average price that UCB.BR shares were previous bought at was EUR 209.407. The current market price is 33.7% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 8,717 (USD $10,170) compared to the previous valuation of UCB SA however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| UNH - UnitedHealth Group Incorporated | HOLD | 0 @ USD 333.49 | USD 0 | The current share valuation price of UNH based on adjusted close was USD 333.49. The average price that UNH shares were previous bought at was USD 424.05. The current market price is -21.4% lower than average price they were purchased at. The value of the holding in UNH has fallen by USD 428,266 compared to the previous valuation of UnitedHealth Group Incorporated |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 484.1 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 484.1. The average price that UTHR shares were previous bought at was USD 430.316. The current market price is 12.5% higher than average price they were purchased at. The value of the holding in UTHR has increased by USD 2,889 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| VEEV - Veeva Systems Inc Class A | HOLD | 0 @ USD 242.28 | USD 0 | The current share valuation price of VEEV based on adjusted close was USD 242.28. The average price that VEEV shares were previous bought at was USD 282.568. The current market price is -14.3% lower than average price they were purchased at. The value of the holding in VEEV has increased by USD 26,394 compared to the previous valuation of Veeva Systems Inc Class A however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 457.36 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 457.36. The average price that VRTX shares were previous bought at was USD 422.613. The current market price is 8.2% higher than average price they were purchased at. The value of the holding in VRTX has fallen by USD 180,140 compared to the previous valuation of Vertex Pharmaceuticals Inc |
| WAT - Waters Corporation | HOLD | 0 @ USD 396.37 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 396.37. The average price that WAT shares were previous bought at was USD 343.572. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in WAT has fallen by USD 19,772 compared to the previous valuation of Waters Corporation |
| WAT - MULETFWATIMETFP | HOLD | 0 @ USD 396.37 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 396.37. The average price that WAT shares were previous bought at was USD 343.572. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in WAT has fallen by USD 19,772 compared to the previous valuation of MULETFWATIMETFP |
| WST - West Pharmaceutical Services Inc | HOLD | 0 @ USD 281.77 | USD 0 | The current share valuation price of WST based on adjusted close was USD 281.77. The average price that WST shares were previous bought at was USD 268.208. The current market price is 5.1% higher than average price they were purchased at. The value of the holding in WST has fallen by USD 3,901 compared to the previous valuation of West Pharmaceutical Services Inc |
| ZBH - Zimmer Biomet Holdings Inc | HOLD | 0 @ USD 93.1599 | USD 0 | The current share valuation price of ZBH based on adjusted close was USD 93.1599. The average price that ZBH shares were previous bought at was USD 97.5443. The current market price is -4.5% lower than average price they were purchased at. The value of the holding in ZBH has increased by USD 258 compared to the previous valuation of Zimmer Biomet Holdings Inc however if the holding was sold on 2025-12-04 this would crystalise an overall loss. |
| ZTS - Zoetis Inc | HOLD | 0 @ USD 120.41 | USD 0 | The current share valuation price of ZTS based on adjusted close was USD 120.41. The average price that ZTS shares were previous bought at was USD 138.556. The current market price is -13.1% lower than average price they were purchased at. The value of the holding in ZTS has fallen by USD 189,166 compared to the previous valuation of Zoetis Inc |